JEVTANA 60 mg concentrate and solvent for solution for infusion

DRUG2 trials

Sponsors

UZ Leuven, Bristol Myers Squibb International Corporation

Conditions

Metastatic Castration-Resistant Prostate CancerOligoprogressive metastatic castration-refractory prostate cancer

Phase 2

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

CompletedCTIS2022-502909-15-00

Bristol Myers Squibb International CorporationMetastatic Castration-Resistant Prostate Cancer

Start: 2017-06-09End: 2025-01-07Target: 69Updated: 2024-11-22

Phase 3

Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial

RecruitingCTIS2022-502254-13-00

UZ LeuvenOligoprogressive metastatic castration-refractory prostate cancer

Start: 2023-12-18Target: 246Updated: 2025-07-18